Literature DB >> 2934514

L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.

M Guttman, P Seeman.   

Abstract

Striatal dopamine receptors were studied using [3H]-spiperone in postmortem tissues of thirty-six patients with Parkinson's Disease. Each tissue was analyzed by the receptor saturation method. In non-treated patients, the D2 dopamine receptor density was elevated in the caudate nucleus and putamen compared to controls. The dissociation constant for [3H]-spiperone was similar in all groups. The elevated density of D2 receptors in non-treated patients may indicate dopaminergic supersensitivity in this disease. The elevated density was reversed with dopamine agonist therapy, but the density was not lower than control tissues.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934514     DOI: 10.1007/bf01245971

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  22 in total

Review 1.  Brain dopamine receptors.

Authors:  P Seeman
Journal:  Pharmacol Rev       Date:  1980-09       Impact factor: 25.468

2.  Dopamine receptors in the denervated striatum: further supersensitivity by chronic haloperidol treatment.

Authors:  A Reches; R H Wagner; V Jackson; E Yablonskaya-Alter; S Fahn
Journal:  Brain Res       Date:  1983-09-19       Impact factor: 3.252

3.  Receptor basis for dopaminergic supersensitivity in Parkinson's disease.

Authors:  T Lee; P Seeman; A Rajput; I J Farley; O Hornykiewicz
Journal:  Nature       Date:  1978-05-04       Impact factor: 49.962

4.  Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: analysis and examples.

Authors:  P Seeman; C Ulpian; K A Wreggett; J W Wells
Journal:  J Neurochem       Date:  1984-07       Impact factor: 5.372

5.  [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy.

Authors:  B Bokobza; M Ruberg; B Scatton; F Javoy-Agid; Y Agid
Journal:  Eur J Pharmacol       Date:  1984-03-23       Impact factor: 4.432

6.  Effect of long-term L-dopa administration on the dopaminergic and cholinergic (muscarinic) receptors of striatum in 6-hydroxydopamine lesioned rats.

Authors:  M Suga
Journal:  Life Sci       Date:  1980-09-08       Impact factor: 5.037

7.  Dopamine agonists reverse the elevated 3H-neuroleptic binding in neuroleptic-pretreated rats.

Authors:  S J List; P Seeman
Journal:  Life Sci       Date:  1979-04-16       Impact factor: 5.037

8.  Dopamine receptors in the Parkinsonian brain.

Authors:  U K Rinne; P Lönnberg; V Koskinen
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

9.  Treatment of Parkinson's disease: problems with a progressing disease.

Authors:  U K Rinne
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

10.  Behavioural and biochemical changes following chronic administration of L-dopa to rats.

Authors:  C Pycock; D Dawbarn; C O'Shaughnessy
Journal:  Eur J Pharmacol       Date:  1982-04-23       Impact factor: 4.432

View more
  13 in total

1.  Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization.

Authors:  M T Martin-Iverson; S M Stahl; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  C E Clarke; S Boyce; M A Sambrook; S M Stahl; A R Crossman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

Review 3.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

4.  Convenient synthesis of 18F-radiolabeled R-(-)-N-n-propyl-2-(3-fluoropropanoxy-11-hydroxynoraporphine.

Authors:  Anna W Sromek; Shaohui Zhang; Vamsidhar Akurathi; Alan B Packard; Wei Li; David Alagille; Thomas J Morley; Ronald Baldwin; Gilles Tamagnan; John L Neumeyer
Journal:  J Labelled Comp Radiopharm       Date:  2014-11-17       Impact factor: 1.921

5.  New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.

Authors:  Young-Cho Kim; Stephanie L Alberico; Eric Emmons; Nandakumar S Narayanan
Journal:  Front Biol (Beijing)       Date:  2015-05-13

6.  Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type.

Authors:  D T Chalmers; D Dewar; D I Graham; D N Brooks; J McCulloch
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

7.  6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.

Authors:  G R Breese; G E Duncan; T C Napier; S C Bondy; L C Iorio; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

8.  Measurement of density and affinity for dopamine D(2) receptors by a single positron emission tomography scan with multiple injections of [(11)C]raclopride.

Authors:  Yoko Ikoma; Hiroshi Watabe; Takuya Hayashi; Yoshinori Miyake; Noboru Teramoto; Kotaro Minato; Hidehiro Iida
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

9.  An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.

Authors:  Florence Véronneau-Veilleux; Philippe Robaey; Mauro Ursino; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-10-21       Impact factor: 2.745

10.  3- and 4-O-sulfoconjugated and methylated dopamine: highly reduced binding affinity to dopamine D2 receptors in rat striatal membranes.

Authors:  E Werle; T Lenz; G Strobel; H Weicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.